Biologics by McKesson to exclusively distribute Cablivi
Independent specialty pharmacy Biologics by McKesson has inked a deal that will expand its offerings. The company announced Thursday that Sanofi Genzyme selected it as the exclusive specialty pharmacy provider of its Cablivi. The Cablivi distribution agreement adds to Biologics by McKesson's six other agreements to distribute treatments for complex conditions.
Cablivi was approved by the Food and Drug Administration on Feb. 6 for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, a rare, life-threatening blood-clotting disorder. Cablivi is the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with the condition. Given the acute nature of the condition, patients need rapid and seamless access to treatment.
To support rapid treatment access for Cablivi and the other therapies it distributes, Biologics by McKesson leverages its PharmacyElite solution that allows the company to extend its offering for both patients and biopharmaceutical customers beyond traditional pharmacy support. Through PharmacyElite, the company offers enhanced patient access services that help eligible patients being treated with Cablivi enroll in copay assistance and patient assistance programs, the company said.
“For more than 25 years, Biologics has helped cancer patients navigate the complex healthcare landscape to gain access to therapies and deliver personalized support designed to improve patient outcomes,” Biologics by McKesson vice president, commercial services Brandon Tom said. “We are proud to continue to expand our offering to the same high-touch specialty pharmacy solutions for patients with complex conditions beyond oncology and look forward to helping these patients get the specialty medication, access and support they need.”
Cablivi was approved by the Food and Drug Administration on Feb. 6 for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, a rare, life-threatening blood-clotting disorder. Cablivi is the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with the condition. Given the acute nature of the condition, patients need rapid and seamless access to treatment.
To support rapid treatment access for Cablivi and the other therapies it distributes, Biologics by McKesson leverages its PharmacyElite solution that allows the company to extend its offering for both patients and biopharmaceutical customers beyond traditional pharmacy support. Through PharmacyElite, the company offers enhanced patient access services that help eligible patients being treated with Cablivi enroll in copay assistance and patient assistance programs, the company said.
“For more than 25 years, Biologics has helped cancer patients navigate the complex healthcare landscape to gain access to therapies and deliver personalized support designed to improve patient outcomes,” Biologics by McKesson vice president, commercial services Brandon Tom said. “We are proud to continue to expand our offering to the same high-touch specialty pharmacy solutions for patients with complex conditions beyond oncology and look forward to helping these patients get the specialty medication, access and support they need.”